| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_644ba7b1554e78445803a700389dcd2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S930-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-31 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-31 |
| filingDate |
2000-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cedc7821708e3d3aa089d1a5d350e53c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22152b6ede2baee5e1dbd39ae59b828d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6733f135d55dc936ca2397aa3702f30b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae94e3d762bd36190488d9480270a6ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_543ff3d7bdeb023b54c8c577cfc71387 |
| publicationDate |
2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6521599-B2 |
| titleOfInvention |
Stable pharmaceutical formulation for intravenous or intramuscular administration of active peptide compounds |
| abstract |
A stable pharmaceutical formulation for intravenous or intramuscular administration of Octreotide, which is characterized in that the vehicle for injection of the peptide or pharmaceutically acceptable salts thereof contains glycine in concentrations ranging from 10 to 60 mM and aqueous solution of hydrochloric acid in sufficient quantity to adjust the pH of the formulation to values between 3.0 and 4.2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006163752-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008287387-A1 |
| priorityDate |
1999-12-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |